Panacea Biotec Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Panacea Biotec Share Price

522.30-24.71 (-4.52%)

Closed
As On: 11 Jun, 2026, 03:49 PM IST
As On: 11 Jun, 2026, 03:50 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	545.00
High	565.00
Low	515.00
Prev Close	547.00
Volume	12,94,387
VWAP(₹)	538.29

Key Metrics

PE Ratio(x)	-595.74
EPS - TTM(₹)	-0.88
MCap(₹ Cr.)	3,199.13
MCap Rank	72
PB Ratio(x)	4.04
Div Yield(%)	-
Face Value(₹)	1.00
52W High(₹)	647.00
52W Low(₹)	292.40
MCap/Sales	2.84
Beta(1 Month)	2.85
BV/Share(₹)	135.33

Panacea Biotec share price insights

Losing Shareholder's Money
Company has reported a negative ROE for 3 consecutive years. (Source: Consolidated Financials)
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 13.27% outperformed its 3 year CAGR of 8.59%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 28.26% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Panacea Biotec Share Price Update
Panacea Biotec Ltd. share price moved down by -4.52% from its previous close of Rs 547.00. Panacea Biotec Ltd. stock last traded price is 522.30
Share Price Value
Today/Current/Last 522.30527.00
Previous Day 547.00547.65

Found Insights useful?

Panacea Biotec Share Price Returns

1 Day	-4.52%
1 Month	37.23%
3 Months	50.28%
1 Year	13.51%
3 Years	330.41%
5 Years	31.73%

Panacea Biotec Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Panacea Biotec Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	169.30	167.47	147.53	172.37	141.12
Total Income Growth (%)	1.09	13.52	-14.41	22.14	-15.55
Total Expenses	169.35	159.13	164.56	164.95	140.12
Total Expenses Growth (%)	6.42	-3.30	-0.24	17.72	-13.37
EBIT	-0.05	8.34	-17.03	7.42	1.00
EBIT Growth (%)	-100.60	-	-329.51	642.00	-81.38
Profit after Tax (PAT)	0.52	3.98	-13.92	4.05	-1.89
PAT Growth (%)	-86.93	-	-443.70	-	-141.81
EBIT Margin (%)	-0.03	4.98	-11.54	4.30	0.71
Net Profit Margin (%)	0.31	2.38	-9.44	2.35	-1.34
Basic EPS (₹)	-0.08	0.65	-2.27	0.66	-0.31

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	116.72	103.15	94.42	117.20	73.99
Total Income Growth (%)	13.16	9.25	-19.44	58.40	-33.79
Total Expenses	115.00	105.58	109.42	120.04	91.38
Total Expenses Growth (%)	8.92	-3.51	-8.85	31.36	-6.99
EBIT	1.72	-2.43	-15.00	-2.84	-17.39
EBIT Growth (%)	-	-	-	-	-228.81
Profit after Tax (PAT)	-0.18	-7.36	-15.64	-6.70	-12.39
PAT Growth (%)	-	-	-	-	-228.39
EBIT Margin (%)	1.47	-2.36	-15.89	-2.42	-23.50
Net Profit Margin (%)	-0.15	-7.14	-16.56	-5.72	-16.75
Basic EPS (₹)	-0.03	-1.20	-2.55	-1.09	-2.02

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	656.67	579.75	584.96	511.61	672.20
Total Revenue Growth (%)	13.27	-0.89	14.34	-23.89	5.89
Total Expenses	683.54	623.70	619.52	601.47	899.60
Total Expenses Growth (%)	9.60	0.67	3.00	-33.14	15.47
Profit after Tax (PAT)	-5.37	-8.37	-1.17	-33.24	1,077.89
PAT Growth (%)	-	-	-	-103.08	-
Operating Profit Margin (%)	-3.25	-7.16	-5.53	-18.57	-7.04
Net Profit Margin (%)	-0.83	-1.49	-0.20	-7.22	163.01
Basic EPS (₹)	-0.88	-1.37	-0.19	-5.43	175.98

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	431.49	326.47	384.51	291.50	248.07
Total Revenue Growth (%)	32.17	-15.09	31.91	17.51	-31.91
Total Expenses	475.34	352.53	380.31	354.25	341.65
Total Expenses Growth (%)	34.84	-7.30	7.35	3.69	-9.41
Profit after Tax (PAT)	-29.88	-15.23	3.55	-87.54	-93.58
PAT Growth (%)	-	-528.93	-	-	-
Operating Profit Margin (%)	-4.48	-3.42	5.00	-20.49	-36.74
Net Profit Margin (%)	-7.22	-4.91	0.98	-34.05	-39.73
Basic EPS (₹)	-4.88	-2.49	0.58	-14.29	-15.28

All figures in Rs Cr, unless mentioned otherwise

Insights

Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 13.27% outperformed its 3 year CAGR of 8.59%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 28.26% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	1,262.17	1,289.75	1,240.67	1,271.17	1,782.51
Total Assets Growth (%)	-2.14	3.96	-2.40	-28.69	51.21
Total Liabilities	433.29	451.92	396.45	426.07	932.55
Total Liabilities Growth (%)	-4.12	13.99	-6.95	-54.31	-33.72
Total Equity	828.88	808.96	816.57	818.46	845.81
Total Equity Growth (%)	2.46	-0.93	-0.23	-3.23	-
Current Ratio (x)	1.47	1.49	1.57	1.71	1.30
Total Debt to Equity (x)	0.03	0.02	0.02	0.02	0.04
Contingent Liabilities	0.00	388.87	378.95	644.43	373.48

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	852.42	869.47	753.64	723.90	761.83
Total Assets Growth (%)	-1.96	15.37	4.11	-4.98	-3.76
Total Liabilities	567.18	548.29	418.50	393.27	342.59
Total Liabilities Growth (%)	3.45	31.01	6.42	14.79	22.38
Total Equity	285.24	292.31	307.49	304.00	393.44
Total Equity Growth (%)	-2.42	-4.94	1.15	-22.73	-19.13
Current Ratio (x)	1.00	0.84	0.74	0.81	1.17
Total Debt to Equity (x)	0.93	0.76	0.39	0.32	0.20
Contingent Liabilities	0.00	381.35	377.08	643.19	372.80

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	16.68	-27.37	-0.10	-422.45	-108.44
Net Cash used in Investing Activities	-40.49	64.98	10.23	430.33	1,282.57
Net Cash flow from Financing Activities	-1.05	-2.66	-2.81	-18.37	-1,175.85
Net Cash Flow	-24.82	34.95	7.32	-10.50	-1.73
Closing Cash & Cash Equivalent	57.31	82.13	47.17	39.85	50.35
Closing Cash & Cash Equivalent Growth (%)	-30.22	74.09	18.37	-20.85	-3.53
Total Debt/ CFO (x)	1.42	-0.55	-150.00	-0.04	-0.28

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	-40.15	3.94	37.27	-10.74	-52.69
Net Cash used in Investing Activities	-18.53	-60.60	-51.01	2.41	39.54
Net Cash flow from Financing Activities	22.54	90.07	12.82	9.01	9.83
Net Cash Flow	-36.09	33.41	-0.91	0.67	-3.32
Closing Cash & Cash Equivalent	2.41	38.50	5.09	6.01	5.33
Closing Cash & Cash Equivalent Growth (%)	-93.74	656.17	-15.22	12.64	-38.40
Total Debt/ CFO (x)	-6.60	56.14	3.19	-9.07	-1.52

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	-0.64	-1.02	-0.14	-4.04	126.99
Return on Capital Employed (%)	-2.27	-4.34	-3.32	-9.09	-4.75
Return on Assets (%)	-0.42	-0.64	-0.09	-2.61	60.47
Interest Coverage Ratio (x)	2.02	-1.36	1.60	-10.43	-0.02
Asset Turnover Ratio (x)	0.50	0.44	0.45	0.30	0.24
Price to Earnings (x)	-344.83	-322.58	-666.67	-20.00	0.84
Price to Book (x)	2.17	3.32	0.91	0.81	1.07
EV/EBITDA (x)	144.50	-496.96	108.22	-9.81	-122.86
EBITDA Margin (%)	1.91	-0.93	1.02	-10.06	-0.43

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	-10.47	-5.20	1.15	-28.79	-23.78
Return on Capital Employed (%)	-3.27	-2.04	3.56	-11.18	-16.79
Return on Assets (%)	-3.50	-1.75	0.47	-12.09	-12.28
Interest Coverage Ratio (x)	0.01	0.63	2.84	-2.80	-8.53
Asset Turnover Ratio (x)	0.48	0.38	0.49	0.35	0.30
Price to Earnings (x)	-60.98	-178.57	212.77	-7.58	-9.71
Price to Book (x)	6.36	9.23	2.42	2.18	2.31
EV/EBITDA (x)	0.00	295.78	21.46	-25.64	-15.80
EBITDA Margin (%)	0.04	3.12	10.86	-10.96	-25.52

Insights

Losing Shareholder's Money
Company has reported a negative ROE for 3 consecutive years. (Source: Consolidated Financials)

Found Financials useful?

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
No Data Available
Pivot Levels
R1 - Pivot
-
S1 -
R2 - S2 -
R3 - S3 -
Average True Range
5 Days 14 Days 28 Days
- - -

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Panacea Biotec	-595.74	3.86	-0.64	-2.27	-0.42	8.59	-3.25	-1.11	-0.88	1.47	0.03	1.42
Bliss GVS Pharma	35.76	3.75	10.82	16.23	8.65	9.06	22.01	14.53	12.23	4.02	0.00	0.02
IOL Chemicals	27.26	2.09	7.65	11.07	5.32	1.42	9.06	5.93	4.69	1.78	0.07	0.62
SMS Pharma	34.82	4.52	12.97	13.84	7.48	19.11	15.75	9.92	11.15	1.81	0.46	6.16
Solara Active Pharma	-377.52	2.23	-0.59	6.48	-0.31	-2.10	6.81	-0.54	-1.68	0.96	0.53	4.35
Add More

Annual Ratios (%)

Choose from Peers

Morepen Labs
Indoco Remedies
Hikal Ltd
Amrutanjan Health Care
Jagsonpal Pharm

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 4,43,94,190 72.48 % 0.00
Pledge 0 0.00 % 0.00
FII 9,77,163 1.60 % 0.24
DII 12,03,607 1.96 % 0.10
MF 713 0.00 % 0.00
Others 1,46,75,786 23.96 % -0.34
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 72.48 72.48 72.48 72.48
Pledge 0.00 0.00 0.00 0.00
FII 1.60 1.36 1.06 0.79
DII 1.96 1.85 1.80 1.52
Mutual Funds 0.00 0.00 0.00 0.00
Others 23.96 24.31 24.65 25.20

Mutual Funds Ownership

MF Ownership as on 30 April 2026

Motilal Oswal BSE Healthcare ETF-G
Equity: Sectoral-Pharma
- 0.02
  Amount Invested (in Cr.)
- 0.04253356%
  % of AUM
- -3.71
  % Change (MoM basis)
Bandhan BSE Healthcare Index Direct-G
Equity: Sectoral-Pharma
- 0.01
  Amount Invested (in Cr.)
- 0.04%
  % of AUM
- 5.97
  % Change (MoM basis)

View all Mutual Fund Schemes

Panacea Biotec Top Searches

Corporate Actions

Recent
Board Meeting
Audited Results & Dividend
May 26, 2026
Board Meeting
Audited Results & Dividend
May 25, 2026
Board Meeting
Quarterly Results
Feb 02, 2026

Announced on	Meeting on
May 26, 2026	May 30, 2026
Audited Results & Dividend
May 25, 2026	May 29, 2026
Audited Results & Dividend
Feb 02, 2026	Feb 11, 2026
Quarterly Results
Nov 04, 2025	Nov 14, 2025
Quarterly Results
Aug 04, 2025	Aug 14, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
May 13, 2011 Sep 19, 2011 75%
May 07, 2010 Sep 16, 2010 25%
Jun 27, 2008 Sep 19, 2008 100%
Jun 14, 2007 Sep 21, 2007 100%
May 23, 2006 Sep 22, 2006 100%
Bonus
No Data Available
Splits
Announced on Ex-Date
Oct 26, 2002 Feb 03, 2003
Split: Old FV10.0| New FV:1.0
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Sep 15, 2025 Sep 30, 2025
-
Feb 27, 2025 Mar 31, 2025
-
Nov 26, 2024 Dec 28, 2024
-
Sep 16, 2024 Sep 27, 2024
A.G.M.
Mar 12, 2024 Apr 13, 2024
-

About Panacea Biotec

Panacea Biotec Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 3,199.13 Crore) operating in Pharmaceuticals sector.

Panacea Biotec Ltd. key Products/Revenue Segments include Pharmaceutical Preparations, Other Operating Revenue, Royalty Income, Export Incentives, Scrap for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 169.30 Crore, up 1.09 % from last quarter Total Income of Rs 167.47 Crore and up 19.97 % from last year same quarter Total Income of Rs 141.12 Crore. Company has reported net profit after tax of Rs -1.00 Crore in latest quarter.

The company’s top management includes Dr.Rajesh Jain, Mr.Sandeep Jain, Mr.Ankesh Jain, Mr.Harshet Jain, Mrs.Ambika Sharma, Mr.Krishan Kumar Jalan, Mr.Mukul Gupta, Dr.Rajender Pal Singh, CA.Rajesh Jain., Dr.Venkatesh Sarvasiddhi, Dr.Sanjay Trehan, Mr.Vinod Goel, Mr.Devender Gupta. Company has Walker Chandiok & Co. LLP as its auditors. As on 31-03-2026, the company has a total of 6.13 Crore shares outstanding.

Panacea Biotec Share Price Today is Rs. 522.30. On previous day, the Panacea Biotec Share Price (NSE) closed at Rs. 607.75, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 72.48% of the stake in Panacea Biotec shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Panacea Biotec stocks was 1.6% as compared to 1.36% in Dec 2025 with increase of 0.24%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 1.96% as compared to 1.85% in Dec 2025 with increase of 0.11%. Out of the total DII holdings in Panacea Biotec shares 0.0% was held by mutual funds. The rest including public held is 23.96%. Panacea Biotec stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Panacea Biotec Dividend: Ever since 1984, Panacea Biotec dividends has been paid out around 17 times. As on 11 Jun, 2026, 03:49 PM IST, The overall dividend yield for Panacea Biotec stands at 0.0%. The last dividend paid was on null (Rs. 0.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. -0.88.

Panacea Biotec Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 169.3 Cr. of sales and 1.09% of quarterly net profit, there have been multiple ups and downs in the Panacea Biotec stock prices in the past few weeks. For example, Panacea Biotec stock price on 3rd of June 2026 was around Rs. 433.6. Panacea Biotec share price now stands at an average of Rs. 522.30. Judging by last week's performance, stock is in up trend.

Panacea Biotec has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Panacea Biotec share.

Historical Prices and Performance:
Panacea Biotec, incorporated in 1984 is a Small Cap company (with a market cap of Rs. 3350.42) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Panacea Biotec stock was -0.64%, -1.02%, -0.14%, -4.04% and 126.99% respectively.
The Panacea Biotec share gave a 3 year return of 350.76% as compared to Nifty 50 which gave a return of 25.06%.
Panacea Biotec announced 0.0% final dividend on null.

Key Metrics:
PE Ratio of Panacea Biotec is -693.21
Prices/Sales Ratio of Panacea Biotec is 2.84
Price/Book Ratio of Panacea Biotec is 4.49

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Panacea Biotec, major competitors and peers include Bliss GVS Pharma, IOL Chemicals, SMS Pharma and Solara Active Pharma. As of Dec 2025, the dividend yield of Panacea Biotec stands at 0.0% while Bliss GVS Pharma, IOL Chemicals, SMS Pharma and Solara Active Pharma stand at 0.35%, 0.77%, 0.1% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at -693.21 and 4.49 respectively.

Leadership of Panacea Biotec :
Vinod Goel is Group CFO, Head Legal & Company Secretary
Devender Gupta is CFO & Head
Rajesh Jain is Chairman & Managing Director
Sandeep Jain is Joint Managing Director
Ankesh Jain is Whole Time Director
Harshet Jain is Whole Time Director
Mukul Gupta is Independent Director
Ambika Sharma is Independent Director
Sanjay Trehan is Director - Technical
Krishan Kumar Jalan is Independent Director
Rajender Pal Singh is Independent Director
Venkatesh Sarvasiddhi is Independent Director
Rajesh Jain. is Independent Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

BSE Healthcare

Address

Ambala-Chandigarh Highway,Lalru, Punjab - 140501

Contact

companysec@panaceabiotec.com

http://www.panaceabiotec.com

Executive Leadership

RJ

Rajesh Jain

Chairman & Managing Director

SJ

Sandeep Jain

Joint Managing Director

AJ

Ankesh Jain

Whole Time Director

HJ

Harshet Jain

Whole Time Director

Show More

Auditors

Suresh Surana & Associates LLP

Walker Chandiok & Co. LLP

FAQs about Panacea Biotec share

1. What's Panacea Biotec share price today and what are Panacea Biotec share returns ?
Panacea Biotec share price is Rs 522.30 as on 11 Jun, 2026, 03:49 PM IST. Panacea Biotec share price is down by 4.52% based on previous share price of Rs. 607.75.
2. What's the market capitalization of Panacea Biotec?
Within the Pharmaceuticals sector, Panacea Biotec stock has a market cap rank of 72. Panacea Biotec has a market cap of Rs 3,199.13 Cr.
3. What is Panacea Biotec's 52 week high / low?
52 Week high of Panacea Biotec share is Rs 647.00 while 52 week low is Rs 292.40
4. What are the returns for Panacea Biotec share?
Return Performance of Panacea Biotec Shares:
- 1 Week: Panacea Biotec share price moved up by 0.38%
5. What is the PE & PB ratio of Panacea Biotec?
The PE ratio of Panacea Biotec stands at -623.91, while the PB ratio is 4.05.

Top Gainers

As on 03:59 PM | 11 Jun 2026

Aegis Logistics

925.90

124.90 (15.60%)

111.45

8.52 (8.28%)

DOMS Industries

2,255.40

136.81 (6.46%)

Blue Jet Healthcare

498.45

28.70 (6.11%)

1,923.80

90.80 (4.96%)

Top Losers

As on 03:59 PM | 11 Jun 2026

Balkrishna Ind.

1,974.00

-109.20 (-5.25%)

1,133.10

-60.31 (-5.06%)

155.70

-7.93 (-4.85%)

166.91

-8.00 (-4.57%)

Adani Transmission

1,466.70

-68.90 (-4.49%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.